Skip to content Skip to footer
Subscribe Now
NEWS

Merz Therapeutics Enrolls First Patients in P-III Studies Evaluating Xeomin for Migraine Prevention

Shots:Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of Xeomin (incobotulinumtoxinA) for migraine preventionBoth studies will recruit ~1,770 adults across 120 sites in North America & Europe, and recruitment in Europe is expected…
August 26, 2025

Read more

VIEWPOINTS_Volker Wacheck_2024
VIEWPOINTS

Volker Wacheck Discusses the Approval of the Lonsurf Combination Drug for the Treatment of Colorectal Cancer

Shots: Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
January 2, 2024

Read more

VIEWPOINTS_Liz Hurlburt_2023
VIEWPOINTS

Liz Hurlburt sheds light on DefenCath, a one of the kind, catheter lock solution

Shots: Liz Hurlburt, Executive Vice President of Clinical & Medical Affairs at CorMedix discusses the revolutionary prospects of DefenCath, a catheter lock solution to prevent CRBSIs in patients receiving hemodialysis via. CVC  Liz sheds light on a serious unmet need for patients affected with catheter-related bloodstream infections. CRBSIs affect approximately 250,000 people annually who receive…
October 31, 2023

Read more